Lois J. Geist

Lois J. Geist

Auto-generated profile, based on publicly available information

Lois J. Geist

Department of Internal Medicine, University of Iowa College of Medicine, Iowa City

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KRKathryn L. Rice
Kathryn L. Rice
NDNaresh Dewan
Naresh Dewan
HBHanna E. Bloomfield
Hanna E. Bloomfield
JGJoseph Grill
Joseph Grill
TSTamara M. Schult
Tamara M. Schult
DNDennis E. Niewoehner
Dennis E. Niewoehner
Rationale: The effect of disease management for chronic obstructive pulmonary disease (COPD) is not well established. Objectives: To determine whether a simplified disease management program reduces hospital admissions and emergency department (ED) visits due to COPD. Methods: We performed a randomized, adjudicator-blinded, controlled, 1-year trial at five Veterans Affairs medical centers of 743 patients with severe COPD and one or more of the following during the previous year: hospital admission or ED visit for COPD, chronic home oxygen use, or course of systemic corticosteroids for COPD. Control group patients received usual care. Intervention group patients received a single 1- to 1.5-hour education session, an action plan for self-treatment of exacerbations, and monthly follow-up calls from a case manager. Measurements and Main Results: We determined the combined number of COPD-related hospitalizations and ED visits per patient. Secondary outcomes included hospitalizations and ED visits for all causes, respiratory medication use, mortality, and change in Saint George's Respiratory Questionnaire. After 1 year, the mean cumulative frequency of COPD-related hospitalizations and ED visits was 0.82 per patient in usual care and 0.48 per patient in disease management (difference, 0.34; 95% confidence interval, 0.15–0.52; P < 0.001). Disease management reduced hospitalizations for cardiac or pulmonary conditions other than COPD by 49%, hospitalizations for all causes by 28%, and ED visits for all causes by 27% (P < 0.05 for all). Conclusions: A relatively simple disease management program reduced hospitalizations and ED visits for COPD. Clinical trial registered with www.clinicaltrials.gov (NCT00126776).

1 July 1991 in Chest
Verified
Journal Article
Closed access
PDF file
MPMichael W. Peterson
Michael W. Peterson
LGLois J. Geist
Lois J. Geist
DSDavid A. Schwartz
David A. Schwartz
SKSteven Konicek
Steven Konicek
PMPope L. Moseley
Pope L. Moseley

1 February 1994 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LGL J Geist
L J Geist
MMM M Monick
M M Monick
MSM F Stinski
M F Stinski
GHG W Hunninghake
G W Hunninghake
Cytomegalovirus (CMV) is an important cause of disease in the immunocompromised patient and CMV infection is associated with predominantly mononuclear inflammatory response. Since products of the CMV immediate early (IE) gene region are potent trans-activators, we used the monocyte cell line THP-1 and a transient transfection assay to determine if these viral proteins upregulate expression of the TNF gene. The IE genes of CMV upregulated TNF gene activity as judged by increases in promoter activity, steady state mRNA, and protein production. The presence or absence of the 3' untranslated region of the TNF gene did not affect gene expression induced by the IE gene products. These studies suggest that activation of TNF gene expression by the CMV IE gene products may, in part, account for the inflammatory response associated with CMV infections.

1 July 1995 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
RMR A Miller
R A Miller
LLL A Lanza
L A Lanza
JKJ N Kline
J N Kline
LGL J Geist
L J Geist
The diagnosis and treatment of Mycobacterium tuberculosis, although difficult in normal hosts, are even more complex in transplant recipients. As a result of the use of immunosuppressive agents, transplant recipients are not only predisposed to primary tuberculous infections, but they are also uniquely at risk for reactivation of latent infection acquired prior to transplantation or transmitted via the donor organ. The diagnosis of pulmonary tuberculosis can be even more elusive in the setting of lung transplantation where other pulmonary complications can make diagnosis difficult. Here we report a case of a patient who died of disseminated M. tuberculosis 12 wk after lung transplantation, and we review tuberculous infections in lung transplant recipients.

1 July 1999 in Psychosomatics
Verified
Journal Article
Closed access
CWCatherine L. Woodman
Catherine L. Woodman
LGLois J. Geist
Lois J. Geist
SVSara Vance
Sara Vance
CLCarolyn Laxson
Carolyn Laxson
KJKelly Jones
Kelly Jones
JKJoel N. Kline
Joel N. Kline

15 September 1996 in Transplantation
Verified
Journal Article
Closed access
LGLois J. Geist
Lois J. Geist
LDLucia Y. Dai
Lucia Y. Dai
Complications after lung transplantation include the development of rejection and an increased incidence of infection, particularly with cytomegalovirus (CMV). Several recent studies have suggested that interleukin(IL)-6 may be used to detect both infection and rejection after lung transplantation. In addition, IL-6 may play a role in the development of bronchiolitis obliterans after transplantation. Because CMV is also associated with the development of bronchiolitis obliterans after transplantation, we determined whether CMV induces IL-6 gene expression. We demonstrated that CMV infection increased both IL-6 protein and mRNA in peripheral blood mononuclear cells. We also demonstrated that the CMV immediate early 1 gene product increased expression of the IL-6 promoter. This effect of the CMV immediate early 1 gene product was dependent upon the presence of specific transcription factor binding sites in the IL-6 promoter. These studies demonstrate that CMV may be an important cofactor in the development of rejection and infection after transplantation through its effects on IL-6.